Clinical factors associated with treatment resistance in major depressive disorder: Results from a European multicenter study

被引:382
|
作者
Souery, Daniel
Oswald, Pierre
Massat, Isabelle
Bailer, Ursula
Bollen, Joseph
Demyttenaere, Koen
Kasper, Siegfried
Lecrubier, Yves
Montgomery, Stuart
Serretti, Alessandro
Zohar, Joseph
Mendlewicz, Julien
机构
[1] Univ Libre Bruxelles, Hop Erasme, Psychiat Serv, Dept Psychiat, B-1070 Brussels, Belgium
[2] Sint Truiden Psychiat Ctr, Dept Psychiat, St Truiden, Belgium
[3] Univ Hosp Gasthuisberg, Dept Psychiat, B-3000 Louvain, Belgium
[4] Med Univ Vienna, Dept Gen Psychiat, Vienna, Austria
[5] Hop La Pitie Salpetriere, INSERM U302, Paris, France
[6] Univ London Imperial Coll Sci Technol & Med, London, England
[7] Ist Sci San Raffaele, Dept Psychiat, Milan, Italy
[8] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel
关键词
D O I
10.4088/JCP.v68n0713
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Objectives: Very few studies have investigated clinical features associated with treatment-resistant depression (TRD) defined as failure of at least 2 consecutive antidepressant trials. The primary objective of this multicenter study was to identify specific clinical and demographic factors associated with TRD in a large sample of patients with major depressive episodes that failed to reach response or remission after at least 2 consecutive adequate antidepressant treatments. Method: A total of 702 patients with DSM-IV major depressive disorder, recruited from January 2000 to February 2004, were included in the analysis. Among them, 346 patients were considered as nonresistant. The remaining 356 patients were considered as resistant, with a 17-item Hamilton Rating Scale for Depression score remaining greater than or equal to 17 after 2 consecutive adequate antidepressant trials. Cox regression models were used to examine the association between individual clinical variables and TRD. Results: Among the clinical features investigated, I I variables were found to be associated with TRD. We found anxiety comorbidity (p <.001, odds ratio [OR] = 2.6), comorbid panic disorder (p <.001, OR = 3.2) and social phobia (p =.008, OR = 2. 1), personality disorder (p =.049, OR = 1.7), suicidal risk (p =.001, OR = 2.2), severity (p =.001, OR = 1.7), melancholia (p =.018, OR 1.5), a number of hospitalizations > I (p=.003, OR 1.6), recurrent episodes (p =.009, OR 1.5), early Age at onset (p =.009, OR = 2.0), and nonresponse to the first antidepressant received lifetime (p =.019, OR = 1.6) to be the factors associated with TRD. Conclusions: Our findings provide a set of 11 relevant clinical variables associated with treatment resistance in major depressive disorder that can be explored at the clinical level. The statistical model used in this analysis allowed for a hierarchy of these variables (based on the OR) showing that comorbid anxiety disorder is the most powerful clinical factor associated with TRD.
引用
收藏
页码:1062 / 1070
页数:9
相关论文
共 50 条
  • [21] A Clinical Risk Stratification Tool for Predicting Treatment Resistance in Major Depressive Disorder
    Perlis, Roy H.
    [J]. BIOLOGICAL PSYCHIATRY, 2013, 74 (01) : 7 - 14
  • [22] FACTORS ASSOCIATED WITH RECOVERY FROM AND RELAPSE INTO MAJOR DEPRESSIVE DISORDER IN THE ELDERLY
    HINRICHSEN, GA
    HERNANDEZ, NA
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 1993, 150 (12): : 1820 - 1825
  • [23] Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study
    Mendlewicz, Julien
    Massat, Isabelle
    Linotte, Sylvie
    Kasper, Siegfried
    Konstantinidis, Anastasios
    Lecrubier, Yves
    Montgomery, Stuart
    Serretti, Alessandro
    Zohar, Joseph
    Souery, Daniel
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2010, 25 (05) : 297 - 301
  • [24] Gender difference in clinical factors associated with comorbid major depressive disorder in patients with panic disorder
    Oh, K. S.
    Lee, D. W.
    Lim, S. W.
    [J]. ASIA-PACIFIC PSYCHIATRY, 2015, 7 : 25 - 25
  • [25] Costs and associated factors with optimal and suboptimal responses to the treatment of major depressive disorder
    Sicras-Mainar, Antoni
    Maurino, Jorge
    Cordero, Luis
    Blanca-Tamayo, Milagrosa
    Navarro-Artieda, Ruth
    [J]. ATENCION PRIMARIA, 2012, 44 (11): : 667 - 675
  • [26] Impact of Body Mass Index on Clinical Outcomes in Major Depressive Disorder - Results From the European GSRD Database
    Kraus, Christoph
    Kautzky, Alexander
    Kadriu, Bashkim
    Deng, Zhi-De
    Bartova, Lucie
    Spies, Marie
    Zarate, Carlos
    Souery, Daniel
    Montgomery, Stuart
    Mendlewicz, Julien
    Zohar, Joseph
    Serretti, Alessandro
    Kasper, Siegfried
    [J]. NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 198 - 198
  • [27] FACTORS ASSOCIATED WITH POOR ADHERENCE IN PATIENTS INITIATING MEDICATION FOR MAJOR DEPRESSIVE DISORDER: INTERIM RESULTS FROM A PROSPECTIVE, LONGITUDINAL STUDY
    Lenderking, W. R.
    Samp, J.
    Hanlon, J.
    Hsieh, R.
    Akhras, K. S.
    Revicki, D. A.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A550 - A550
  • [28] Recurrence of major depressive disorder across different treatment settings: Results from the NESDA study
    Hardeveld, Florian
    Spijker, Jan
    De Graaf, Ron
    Hendriks, Sanne M.
    Licht, Carmilla M. M.
    Nolen, Willem A.
    Penninx, Brenda W. J. H.
    Beekman, Aartjan T. F.
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2013, 147 (1-3) : 225 - 231
  • [29] The efficacy and safety of levomilnacipran in the treatment of major depressive disorder: Results from a phase III clinical trial
    Bose, A.
    Chen, C.
    Gommoll, C.
    Ruth, A.
    Hussainzada, N.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 182 - 182
  • [30] The efficacy and safety of levomilnacipran in the treatment of major depressive disorder: results from a phase III clinical trial
    Bose, A.
    Chen, C.
    Gommoll, C.
    Ruth, A.
    Terner-Rosenthal, J.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S261 - S262